Discover Our Group:

Berlin-Chemie has been developing, manufacturing and distributing pharmaceutical products for over 130 years and has been a wholly owned subsidiary of the Menarini Group, the leading Italian pharmaceutical company, since 1992. 

Responsibility is a top priority at Berlin-Chemie. We not only make an important contribution to healthcare, but also put our values into practice through various social initiatives.

Discover More about Global Responsibility

From school kits to free meals and medicines, to caring for the environment around the world. In Menarini, being responsible means translating our values into concrete actions that are good for others and good for the planet

Berlin-Chemie – a strong partner. Our many years of experience and the success of joint projects make us the partner of choice. 

Discover More about Global Partnering

Menarini has in-depth know-how in many important therapeutic areas, thanks to many years of excellent market introduction, marketing and sales capabilities as well as expertise in regulatory aspects and market access. Collaboration is the key to great success, and at Menarini, partnership is part of the DNA.

Our holistic and professional health management offers doctors individual counselling, training or workshops, events and lectures on many topics, depending on their needs.

Our Medical Hub acts as a central point of contact for doctors and healthcare professionals. Here you will find all the information about our medications, additional service and training opportunities.

Welcome to the News & More section. Here you will find general information in the form of press releases, news and the latest graphical material. 

Menarini Blog

Follow Us

We employ professionals with a wide variety of career backgrounds and are employers who care about their staff. Together, we stand for innovation and reliability.

Our Job Portal

Find out about our current vacancies at Berlin-Chemie directly on our career portal.

Menarini Group News

2016 - 12 - 19

Press Release

Tirana, 18 October 2016 – The project for a “Paediatric network against ill- treatment of minors”, launched and supported by the pharmaceutical company, Menarini, together with Telefono Azzurro, the Italian Federation of Paediatricians, and the Association of Italian Paediatric Hospitals, has grown beyond Italian borders.

Dr. Luigi Nigri, head of the project on behalf of the Italian Federation of Paediatricians, opened the main session of the International Congress of the Albanian Pediatric Society in Tirana, presenting the project to more than 500 paediatricians, not only from the Balkans but also countries such as Romania, Switzerland, Turkey and others.



A huge amount of interest and enthusiasm was expressed for the initiative, to the extent that the representatives of the Albanian government present were immediately questioned regarding the possible development of an equivalent project.

The project, originated in Italy and the first of its kind in the world, foresees  the creation of a network of 15,000 paediatricians and general practitioners deployed over the entire Italian territory who act as ‘sentinels’ in the fight against child abuse. These physicians, who have been 'trained' on the skills needed to recognise the unexpressed ‘sentinel’ warning signs of child abuse,  shall in turn become reference people for their colleagues on a local level, providing qualified information and advice. This project for the creation of an anti-abuse network was launched last May in the city of Florence and is supported  by Menarini with an investment of one million Euro. Local training courses are currently on-going in numerous Italian regions.

“This is a project of great scientific and social importance”, commented Professor Anila Godo, Chairperson of the Albanian Pediatric Society, Director of the Department of Paediatrics of the Madre Teresa University Hospital and ex Minister of Health for Albania, “which demonstrates just how efficient the Italian paediatric system is in responding to the needs of children and their families in terms of health and well-being. Menarini is giving a clear signal and is setting an example by demonstrating its close relationship with the world of paediatrics. This not only includes pharmaceutical research but also supporting projects like these which reach out to every one of us. We must hope that this example will be followed by organisations with important financial influence in every country.”

Professor Ersilia Buonomo, from the department of Biomedicine and Prevention at the University of Tor Vergata in Rome, has always been active in this area. Commenting on the project, she highlighted that “Italian paediatricians, historically known for being attentive to the social needs of children, have come forward to fill a gap in the healthcare system regarding a complex and previously overlooked need. I hope that it will be possible to create a network involving all social and institutional entities, including associations of volunteers, for an efficient management of this delicate problem, for the benefit of children and their families.”